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ChemoresistanceAstrocyte elevated gene-1 (AEG-1), upregulated in various types of malignancies including colorectal
cancer (CRC), has been reported to be associated with the carcinogenesis. MicroRNAs (miRNAs) are
widely involved in the initiation and progression of cancer. However, the functional signiﬁcance of
AEG-1 and the relationship between AEG-1 and microRNAs in human CRC remains unclear. The aim of
this study was to investigate whether AEG-1 could serve as a potential therapeutic target of human
CRC and its possible mechanism. We adopted a strategy of ectopic overexpression or RNA interference
to upregulate or downregulate expression of AEG-1 in CRC models. Their phenotypic changes were ana-
lyzed byWestern blot, MTT and transwell matrix penetration assays. MicroRNAs expression proﬁles were
performed using microarray analysis followed by validation using qRT-PCR. Knockdown of AEG-1 could
signiﬁcantly inhibit colon cancer cell proliferation, colony formation, invasion and promotes apoptosis.
Conversely, upregulation of AEG-1 could signiﬁcantly enhance cell proliferation, invasion and reduced
apoptisis. AEG-1 directly contributes to resistance to chemotherapeutic drug. Targeted downregulation
of AEG-1 might improve the expression of miR-181a-2⁄, -193b and -193a, and inversely inhibit miR-31
and -9⁄. Targeted inhibition of AEG-1 can lead to modiﬁcation of key elemental characteristics, such as
miRNAs, which may become a potential effective therapeutic strategy for CRC.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Astrocyte elevated gene (AEG)-1 was cloned as a human immu-
nodeﬁciency virus (HIV)-1 and tumor necrosis factor a (TNF-a)-
inducible gene in primary human fetal astrocytes by a rapid
subtraction hybridization approach [1,2], which is a downstream
target molecule of Ha-ras and c-myc mediating their tumor pro-
moting effects [3]. AEG-1 is overexpression in multiple types of
human cancers including breast cancer, gastric cancer, hepatocel-
lular carcinoma, ovarian cancer, prostate cancer, nonsmall cell lung
carcinoma, colorectal carcinoma and esophageal squamous cell
carcinoma [4–11]. As a multifunctional oncoprotein, AEG-1 canenhance phenotypes characteristic of malignant aggressiveness,
including proliferation, invasion, migration, neovascularization,
chemoresistance and senescence [12]. AEG-1 plays a central role
in several signaling pathway, including Ha-ras-mediated oncogen-
esis through the phosphatidylinositol 3-kinase (PI3K)/Akt [13], and
Wnt/b-catenin signaling via ERK42/44 activation and upregulated
lymphoid-enhancing factor 1/T cell factor 1 (LEF1/TCF1) [8]. AEG-
1 directly contributes to the resistance of chemotherapeutic drugs
[14], such as 5-ﬂuorouracil (5-FU). AEG-1 augments expression of
the transcription factor LSF that regulates the expression of thymi-
dylate synthase (TS), a target of 5-FU, and dihydropyrimidine
dehydrogenase (DPYD) that catalyzes the initial and rate-limiting
step in the catabolism of 5-FU [13]. These data indicate that
AEG-1 plays a central role in regulating diverse aspects of cancer
pathogenesis. Targeted inhibition of AEG-1 might lead to an effec-
tive therapeutic strategy for cancer.
MicroRNAs have recently taken center stage in the ﬁeld of hu-
man molecular oncology molecules by miR genes which are able
to control the expression of a large number of cellular proteins
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NAs expression could be an important factor in the development
and maintenance of the neoplastic state. We hypothesize that
AEG-1 could be able to alter miRNAs expression pattern to pro-
mote the tumor development.
Colorectal carcinoma (CRC) is one of the most common malig-
nancies worldwide. Song et al. [9] have reported AEG-1 expression
may be associated with tumor progression in CRC and high AEG-1
expression correlates with poor overall survival in the CRC patients.
Our previous study also show that AEG-1 was overexpressed in co-
lon cancer and associatedwith the prognosis (submitted). However,
the function of AEG-1 in pathogenesis of CRC has not been clearly
known. In this study, we applied shRNA against AEG-1 and transfec-
ted AEG-1 overexpression mediated by lentivirus to investigate co-
lon cancer cell growth in vitro. Microarray was performed to detect
themodiﬁcation ofmiR expression pattern, in order to identify AEG-
1 as a molecular target for cancer therapy.2. Materials and methods
2.1. Cell lines and culture
Human colon cancer cell lines Lovo, HT29, CaCO2, HCT116,
SW1116, SW620 and SW480 (Chinese Type Culture Collection, Bei-
jing, China) were maintained in Dulbecco’s modiﬁed Eagle’s med-
ium (DMEM, Invitrogen, Carlsbad, CA, USA) supplemented with
10% heat-inactivated fetal bovine serum (FBS, Gibco, AUS) at
37 C in an atmosphere of 5% CO2 with humidity.
2.2. Vectors and retroviral infection
pMSCV/AEG-1-overexpressing human AEG-1 was generated by
subcloning the PCR-ampliﬁed human AEG-1 coding sequence into
pMSCV vector. The preparation of pure recombinant AEG-1 poly-
peptide was done according to a standard protocol. To silence
endogenous AEG-1, two short hairpin RNAi oligonucleotides were
cloned into the pSuper-retro-puro vector to generate pSuper-ret-
ro-AEG-1-RNAis, respectively. The following oligonucleotides for
AEG-1 were synthesized through Genepharma as shown in Table 1.
Recombinant retroviral vectors were produced by transient
cotransfection. Viral infections were done serially, and stable cell
lines expressing AEG-1 or AEG-1 RNA is were selected for 10 days
with 0.5 lg/ml puromycin 48 h after infection. After 10-day selec-
tions, the cells were harvested for Western blot analysis.
2.3. Western blot analysis
Proteins were extracted after break-down of cells by SDS boiling
method. Proteins were quantiﬁed by Bradford method. 50 lg of
protein underwent SDS–PAGE and was transferred to PVDF mem-
brane afterward. It was then sealed at room temperature for 1 h.
The primary antibodies, rabbit anti-human AEG-1 antibody (Invit-
rogen, Carlsbad, CA) was added at a ratio of 1:1000, and incubated
overnight at 4 C. The membrane was washed with TBST. Then, the
secondary antibody, mouse anti-rabbit IgG/HRP antibodiesTable 1
Targeted AEG-1 sequences were chemically synthesized by Genepharma (Shanghai,
China).
Name Sequences
AEG-1-RNAi1 s: GCAGCAAGGCAGTCTTTAAGT
as: ACTTAAAGACTGCCTTGCTGC
AEG-1-RNAi2 s: GGAACGGTACGCTATACAACG
as: CGTTGTATAGCGTACCGTTCC(Amersham Biosciences), was added at a ratio of 1:3000, and incu-
bated at room temperature for 1 h. The membrane was washed
three times and reacted with chemiluminescent agent for 5 min.
It was then ECL tabletting, exposed, and displayed. The amount
of each protein sample was controlled by GAPDH. Three indepen-
dent experiments were performed.2.4. Cell proliferation assay
Cells were trypsinized and plated in 96-well plates with
3.0  103 cells in 100 ll of the medium and allowed to attach for
24 h, then 10 ll of MTT (5 mg/ml in PBS) was added for 4 h incuba-
tion at 37 C after 4, 24, 48, 72 h, respectively. Subsequently the
formazan crystals were solubilized with 150 ll DMSO for 10 min.
The absorbance was measured using a Microplate Reader
(Bio-rad 680, Bio-rad, USA) with a test wavelength of 570 nm
and all experiments were performed in triplicate. The cell prolifer-
ation curve was plotted using the absorbance at each time point.
Three independent experiments were performed.2.5. Colony formation assay
Cells were trypsinized, counted, and seeded for the colony
forming assay in 6-well plate at 100 cells per well. After incubation
for 10 days, colonies were stained with Gimsa and the numbers of
positive cells counted. Colonies containing more than 50 cells were
scored, and triplicates were counted in each treatment. Three inde-
pendent experiments were performed.2.6. Transwell matrix penetration assay
2  104 cells were plated into the top side of polycarbonate
Transwell ﬁlter coated with Matrigel in the upper chamber of the
BioCoat™ Invasion Chambers (BD, Bedford, MA) and incubated at
37 C for 24 h, followed by removal of cells inside the upper cham-
ber with cotton swabs. Migratory and invasive cells on the lower
membrane surface were ﬁxed in 1% paraformaldehyde, stained
with Gimsa, and counted (Ten random 100 ﬁelds per well). Cell
counts were expressed as the mean number of cells per ﬁeld of
view. Three independent experiments were performed.2.7. Cell cycle and apoptosis analysis
Detection of apoptosis and cell cycle by ﬂow cytometry was
performed using the ApoScreen Annexin V Apoptosis Kit (South-
ernBiotech, USA) and PI kit (Becton Dickinson, CA, USA). The trans-
fected cells were harvested with trypsinization. The staining was
performed according to the producer’s manual. Flow cytometry
(Becton Dickinson, CA, USA) was performed immediately after
staining. Three independent experiments were performed.2.8. MicroRNA array hybridization
Total RNA was extracted from cells by using TRIzol (Invitrogen,
Carlsbad, CA) and the concentration of total RNA was evaluated by
measuring the absorbance at 260 nm. We examined the expression
proﬁle of miRs by using a Human Affymetrix microarray, which is
equipped with 3440 oligonucleotide probes for the detection of hu-
man miRs. Each sample was independently hybridized to one ar-
ray. Hybridization signals were analyzed by using an Affymetrix
GeneChip Command Console software. The hybridized signal
intensities were normalized by the intensities of synthetic oligonu-
cleotide DNA probes.
Fig. 1. AEG-1 expression in CRC cell lines. (A) AEG-1 expression was examined in
CRC cell lines including SW1116, HCT116, SW480, SW620, Lovo, HT29 and CaCO2
by Western blot analysis. (B) Knockdown of AEG-1 in speciﬁc shRNAs-transduced
stable HCT116 cells. AEG-1 expression decreased in HCT116 transfected with AEG-1
RNAi1 or RNAi2 compared with the control and vector group; stable AEG-1
overexpression in SW1116 was shown by Western blot analysis.
340 S. Huang et al. / Biochemical and Biophysical Research Communications 444 (2014) 338–3452.9. Quantitative RT-polymerase chain reaction assay for miRNA
Total RNAwas extracted fromcells by TRIzol (Invitrogen, Carlsbad,
CA)was reverse-transcribed to cDNA by using 365 speciﬁc stem-loop
reverse transcription primers. In order to examine the expression le-
vel ofmaturemiR-181a-2⁄, -31, -9⁄, -193a and -193b indetailwe per-
formed TaqMan MicroRNA Assays (Applied Biosystems, Foster City,
CA) by using the qPCR System with the following thermal cycling
parameters: 94 C for 2 min, followed by 40 cycles of ampliﬁcation
(94 C for 10 s, 60 C for 20 s, 72 C for 30 s). The absorbance values
of theSYBRGreen I ineach tubeweredetectedat the endof eachcycle.
The melting curves of PCR products were also graphed after PCR
ampliﬁcation, followed by incubation at 12 C. The expression level
of the miR in each sample was measured and was normalized to U6
expression, as an internal control. Calculationof theCtvaluewasdone
by using a second derivative maximummethod, and relative quanti-
ﬁcationwas analyzed by a comparative Ctmethod. Final results illus-
trated in Fig. 4 were presented as log2 of N-fold change. All reactions
were run in triplicate. The PCR primer pairs for miRs were obtained
commercially from Ribobio Co. (Table 2).
2.10. Cell viability assay
Cells were seeded at a density of 3  103 cells in 96-well plates
(Corning, NY, USA). After overnight culture, they were exposed to
various concentrations of 5-Fu for 72 h in a CO2 incubator. MTT as-
say as described above was used to detect the chemo-sensitivity of
cells. Absorbance values at 570 nm of each well were expressed as
percentages relative to controls, and the concentrations resulting
in 50% inhibition of cell growth (IC50 values) were calculated. Three
independent experiments were performed.
2.11. Statistical analysis
Three independent experiments were performed. Results were
presented as means ± S.D. Statistical analyses were performed
using the SPSS 13.0 statistical software. The two-tailed Student’s
t test or ANOVA were used to analyse. P-value <0.05 was consid-
ered statistically signiﬁcant.
3. Result
3.1. AEG-1 expression in CRC cell lines and downregulation or
upregulation of AEG-1 in vitro
AEG-1 expression was examined in CRC cell lines including
SW1116, HCT116, SW480, SW620, Lovo, HT29 and CaCO2 by Wes-tern blot analysis. However, AEG-1 protein expression was higher
in HCT116, SW480, SW620, and relatively lower in SW1116, Lovo,
HT29 and CaCO2. Furthermore, AEG-1 expression was highest in
HCT116 and lowest in SW1116 (Fig. 1A). As shown in Fig. 1B, trans-
fection of HCT116 with AEG-1 RNAi1 or RNAi2 resulted in the
knockdown of AEG-1 at translation levels in HCT116 cell line and
AEG-1 RNAi1 downregulation effect seems more obvious than
RNAi2, while transfection of SW1116 with stable AEG-1 plasmid
upregulates the expression of AEG-1 in Western Blot.
3.2. Knockdown of AEG-1 inhibits cell proliferation, colony formation
and invasion
In order to examine the role of AEG-1 on CRC cell proliferation
and invasion, we constructed AEG-1 shRNA in HCT116 cell line
and examined the effect of AEG-1 RNAi1. MTT assay results indi-
cated that AEG-1-RNAi1 signiﬁcantly decreases cell proliferation
by 29.51% in HCT116 at 72 h after plating (Fig. 2A). This phenome-
non was further conﬁrmed by colony formation assay. As shown in
Fig. 2B, the downregulation of AEG-1 could signiﬁcantly decrease
the colony formationofHCT116. Around2 timesmore colonieswere
formed by control cells than that in AEG-1-RNAi1 HCT116 cells. Fur-
thermore, AEG-1-RNAi1 signiﬁcantly decreased HCT116 cell inva-
sive ability compared to control group (Fig. 2C). The mean number
of invasive HCT116 cell lines with AEG-1-RNAi1 and the control
group was 25 and 245 per ﬁeld of view, respectively (P < 0.05).
3.3. Upregulation of AEG-1 enhances proliferation, invasion and colony
formation
To further investigate the biological role of AEG-1 expression in
CRC progression, CRC cell line SW1116 was established to stably
overexpress AEG-1. MTT assay results indicated that AEG-1-in-
fected SW1116 cells grew faster, with 1.53-fold and 1.41-fold more
cells than the control by 48 and 72 h after plating (Fig. 2D). In
Transwell Matrix Penetration Assay, AEG-1 upregulation signiﬁ-
cantly increased the invasive ability of SW1116 cells compared
to control group. The difference of cell invasion between SW1116
with stable AEG-1 overexpression and the control group was sig-
niﬁcant (P < 0.01; Fig. 2F). However, AEG-1 had no impact on col-
ony formation (Fig. 2E). Although the colony formation rates
between themwere not statistically signiﬁcant, increases in colony
formation size were obvious.
3.4. Knockdown of AEG-1 accumulates G0/G1-phase cells and
promotes apoptosis in CRC cells
Cell proliferation inhibited by knockdown of AEG-1 was shown
above. To reveal mechanism involved in proliferation inhibition,
we analyzed cell cycle by using ﬂow cytometry. As shown in
Fig. 3A and B, knockdown of AEG-1 resulted in accumulation in
the G0/G1-phase cell and overexpress of AEG-1 resulted in increase
of S phase cell. We also evaluated apoptotic levels by using ﬂow
cytometry. The apoptotic cell fraction was 7.67% and 14.97% in
AEG-1RNAi1 and control group, 12.36% and 6.86% in SW1116-vec-
tor and AEG-1 group (Fig. 3C).
3.5. MicroRNA expression
To identify AEG-1-downstream genes, we performed Affymetrix
microarray containing 3440 human miRNA probes to identify the
comprehensive modiﬁcation of miRNA expression proﬁles in
HCT116 and SW1116 cell lines, and chose the level of 2-fold
change of expression as selection criteria. The analysis of miR gene
expression showed that a number of genes were affected by
upregulation or downregulation of AEG-1. We analyze that there
Fig. 2. Downregulation or upregulation of AEG-1 affects cell growth, invasion and tumorigenicity activity. (A) Silencing AEG-1 inhibits cell growth as determined by 3-(4,5-
dimethy1-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assays. (B) Silencing AEG-1 inhibits cell growth as determined by colony formation assays. (C) Silencing
AEG-1 dramatically inhibited invasion of HCT116 compared with the control group by transwell matrix penetration assay. (D) Overexpression of AEG-1 stimulates SW1116
cell proliferation as determined by MTT assays. (E) Colony formation assay shows that the upregulation of AEG-1 promotes cell growth. (F) Upregulation of AEG-1
dramatically increased invasion of SW1116 compared with the control group by transwell matrix penetration assay. Error bars represent mean ± SD from three independent
experiments. ⁄P < 0.05, ⁄⁄P < 0.01.
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sely down-regulated in SW1116 treated group. Oppositely, there
were 8 miRNAs down-regulated in HCT116 treated group and in-
versely up-regulated in SW1116 treated group (data not shown).
Around the 19 miRNAs, 5 miRNAs (miR-181a-2⁄, -31, -9⁄, -193a
and -193b) were chosen to be validated because their expression
was great difference between both cell lines after treatment.
The expression of selected miRNAs was then validated by qRT-
PCR. Data were transformed in N-fold gene expression of target
miRNA with respect to the expression of the same miRNA in the
control sample. Both cell lines showed a opposite trend of up- or
down-regulation of AEG-1 induced miRNA changes. miR-181a-2⁄,-193a and -193b were found to be down-regulated in SW1116-
AEG-1 cells but up-regulated in HCT116-RNAi1 cells. miR-31 and
-9⁄ were found to be down-regulated in HCT116-RNAi1 cells but
up-regulated in SW1116-AEG-1 cells (Fig. 4A). The 5 miRNAs all
showed signiﬁcant expression changes with respect to controls in
both cell lines, although miR-193a did not reach the level of the
2-fold change of expression in HCT116 cells (Table 3).
qRT-PCR analysis showed that miR-181a-2⁄, -193b, and -193a
expression were inversely correlated with AEG-1 expression, but
miR-31 and miR-9⁄ were in accordance with AEG-1 expression.
Knockdown of AEG-1 by RNAi in CRC cells, similar to the 3 miRs
(miR-181a-2⁄,-193b and -193a) overexpression, suppressed tumor
Fig. 3. Effect of AEG-1 downregulation and upregulation on the cell cycle and apoptosis in HCT116 and SW1116 cells. (A) Representative cell cycle distribution results are
shown. (B) The population of G0/G1 phase was signiﬁcantly increased in HCT116-RNAi1 cell compared to control group and the population of S phase was obviously
increased in SW1116-AEG-1 cell compared to control group (⁄P < 0.05). (C) Annexin V APC-A staning discriminates cells in early (lower right quadrant) and late apoptotic and
necrotic states (upper right quadrant). The apoptosis rates were 14.97 ± 3.03% and 7.67 ± 1.21% in HCT116-RNAi1 and control group, 12.36 ± 2.06% and 6.86 ± 1.45% in
SW1116-vector and AEG-1 group, respectively (⁄⁄P < 0.01). These experiments were performed in triplicate.
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miR-31 and -9⁄ appears to be associated with tumor development.
3.6. AEG-1 knockdown increases 5-FU cytotoxicity
In order to further examine the contribution of AEG-1 to the
sensitivity to 5-FU, we determined various concentration of 5-FUon the 2 colon cancer cell lines. The growth of both HCT116 and
SW1116 colon cancer cells were suppressed by the treatment of
5-Fu. From 0 to 16 uM of 5-FU, AEG-1 knockdown increased 5-FU
cytotoxicity in a dose-dependent manner than control. The IC50
values of 5-Fu for HCT116 untreated and treated cells were 8.13
and 2.77 uM, respectively (Fig. 4B and Table 4). These results
demonstrated that transfection of AEG-1 RNAi1 increased the
Fig. 4. The expression of 5 miRNAs was validated by qRT-PCR and AEG-1 confers resistance to 5-FU. (A) 5 miRNAs (miR-181a-2⁄, -31, -9⁄, -193a and -193b) were validated.
miR-181a-2⁄, -193a and -193b were found to be down-regulated in SW1116-AEG-1 cells but up-regulated in HCT116-RNAi1 cells. miR-31 and -9⁄ were found to be down-
regulated in HCT116-RNAi1 cells but up-regulated in SW1116-AEG-1 cells (⁄P < 0.05, ⁄⁄P < 0.01). (B) HCT116-RNAi1 and control cells were treated with the indicated
increasing concentrations of 5-FU. (C) SW1116-AEG-1 and control cells were treated with the indicated increasing concentrations of 5-FU. IC50 values were calculated.
Table 3
The fold change of 5 miRNAs in 2 treated group compared to the control.
miRNA Fold change
SW1116-AEG-1 HCT116-RNAi1
miR-181a 0.30 3.41
miR-31 5.60 0.52
miR-9a 4.67 0.06
miR-193b 0.46 5.62
miR-193a 0.25 1.29
Table 4
The IC50 values of 2 groups and their P-value.
Control Treatment P-value
IC50 HCT116 8.13 ± 0.66 2.77 ± 1.39 <0.05
(uM) SW1116 14.35 ± 0.79 18.30 ± 1.91 <0.05
Table 2
The sequence of 5 miRNAs.
miRNA Sequence
miR-181a-2⁄ ACCACUGACCGUUGACUGUACC
miR-31 UGCUAUGCCAACAUAUUGCCAU
miR-9⁄ AUAAAGCUAGAUAACCGAAAGU
miR-193b CGGGGUUUUGAGGGCGAGAUGA
miR-193a UGGGUCUUUGCGGGCGAGAUGA
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SW1116 cells were 14.35 and 18.30 uM, which indicated
SW1116-AEG-1 cells that expression more AEG-1 were more resis-
tant to 5-FU compared to the control cells (Fig. 4C and Table 4).
Inhibition of AEG-1 by shRNA signiﬁcantly increased 5-FU-medi-
ated killing in the HCT116 cells. It should be noted that AEG-1 RNAi
had a more pronounced effect on 5-FU-mediated killing compared
to control group indicating that AEG-1 controls multiple effectors
mediating 5-FU killing.4. Discussion
Carcinogenesis of CRC is the result of the progressive acquisi-
tion of multiple oncogenic factors through the accumulation of ge-
netic or epigenetic alterations. Aberrant AEG-1 expression has
been observed in multiple types of human cancers including CRC.
AEG-1 expression was markedly correlated with the UICC stage,
TNM classiﬁcation, and histological differentiation in the CRC pa-
tients. High AEG-1 expression correlates with poor overall survival
in the CRC patients, whereas patients with lower AEG-1 expression
had better survival [9]. Our earlier data also have demonstrated
that AEG-1 expression was increased in human colon cancer tis-
sues compared to normal colon tissues. The expression level of
AEG-1 was correlated with the clinical stage of CRC. Multivariate
analysis strongly suggested that AEG-1 might be an independent
and valuable biomarker for the prediction of prognosis of CRC
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AEG-1 as a therapeutic target of CRC and its possible mechanism.
Numerous reports have demonstrated that oncoprotein AEG-1
is linked to the biological processes such as cancer cell survival,
apoptosis, migration and invasion. To investigate whether the gain
or loss function of AEG-1 is related to the progression of CRC, we
adopted a strategy of ectopic overexpression or a small hairpin
RNAi to upregulate or downregulate expression of AEG-1 in CRC
models. After transfection with AEG-1 shRNA, protein level of the
AEG-1 gene decreased, and meanwhile cell growth inhibited, col-
ony-forming ability decreased and apoptosis increased. Mean-
while, upregulation of AEG-1 enhanced cell proliferation,
invasion properties and inhibited apoptosis, but not the colony for-
mation rates. Therefore, our data conﬁrmed that AEG-1 served in
regulating both cell proliferation and survival, which is the same
as other reports. For instance, Zhang et al. [15] have reported that
AEG-1 enhanced migration and invasion of CRC. Emdad et al. [16]
have conﬁrmed that AEG-1 is indeed a transforming oncogene and
show that stable expression of AEG-1 in normal immortal cloned
rat embryo ﬁbroblast (CREF) cells induces morphological transfor-
mation and enhances invasion and anchorage-independent growth
in soft agar.
The oncogenic role of AEG-1 in tumor development and pro-
gression has been reported to be associated with several pathways.
Our reports show that knockdown of AEG-1 resulted in accumula-
tion in the G0/G1 phase and overexpress of AEG-1 resulted in in-
crease of S phase cell. The underlying mechanisms in CRC are
still unclear, maybe associated with the PI3K/AKT signaling path-
way. AEG-1 play a critical role in Ha-ras-mediated oncogenesis
through the PI3K/AKT signaling pathway [3,17]. AEG-1 cooperates
with Ha-ras to promote transformation and its overexpression
augments invasion of transformed cells demonstrating its func-
tional involvement in Ha-ras-mediated tumorigenesis. Kikuno
et al. also revealed that aberrant AEG-1 expression as a positive
auto-feedback activator of AKT and as a suppressor of FOXO3a in
prostatic cancer cells [10]. We also ﬁnd that AEG-1 can enhance
cell invasion property in CRC which may be associated with the
NF-jB pathway. Cellular motility and extracellular matrix degra-
dation are twomajor determinants of cancer cell invasion. Invasion
involves secretion of chemokines that help in tumor cell motility in
a deﬁned direction and proteolytic enzymes involved in extracellu-
lar matrix degradation. Emdad et al. documented that AEG-1 exerts
its effects by activating the NF-jB pathway [18]. AEG-1 increases
in malignant glioma and regulates in vitro invasion and migration
of malignant glioma cells by activating the NF-KB signaling path-
way [19]. AEG-1 can physically interact with the p65 subunit of
NF-jB and modulate its function in the nucleus.
miRNAs have recently taken center stage in the ﬁeld of human
molecular oncology and have been increasingly recognized as key
regulators in many cancers. Even a small change in miRNA expres-
sion could cause a profound effect on gene expression of hundreds
of mRNAs. The 5 miRNAs whose expression was great difference
between two cell lines after treatment may be performed as the
effectors, contributing to tumorigenesis. miR-181a-2⁄, -193a and
-193b were found to be down-regulated in SW1116 treated group
but up-regulated in HCT116 treated group. AEG-1 inhibited the
expression of the 3 miRNAs and shRNA-mediated inhibition of
AEG-1 signiﬁcantly increased their expression. It means that the
3 miRNAs may perform as anti-oncogens. miR-193b inhibited cell
proliferation, migration and invasion has been observed in multi-
ple types of human cancers including nonsmall cell lung carci-
noma, Melanom and hepatocellular carcinoma [20–22] Some
research identiﬁed that miR-193a regulating proliferation and
apoptosis, and inhibiting cellular transformation by directly target-
ing PLAU and K-Ras. Expression of miR-193a is inversely correlated
with PLAU and K-Ras in human CRC [23]. Novel miRNA (miR-181a-2⁄) has been reported rarely and its function remain unclear. We
inferred that the 3 miRs (miR-193b,-193a, -181a-2⁄) involved in
not only the regulation of cell proliferation and invasion, but also
the chemotherapy response. miR-31 and -9⁄ were found to be
down-regulated in HCT116 treated group but up-regulated in
SW1116 treated group. AEG-1 enhances the expression of miR-
31 and miR-9⁄ by 5.6 and 4.67-fold. We conclude that miR-31
and miR-9⁄ plays oncogenetic functions in CRC. A lot of researches
had conﬁrmed that miR-31 played as oncogenetic role [24,25].
Suppression of miRNA-31 increases sensitivity to 5-FU at an early
stage, and affects cell migration and invasion in HCT-116 colon
cancer cells. The biochemical function of the 5 miRNAs has been
characterized cancer association.
We explored the therapeutic role of AEG-1 in combination with
chemotherapeutic drug, such as 5-FU. Our results suggest that 5-
FU could be more effective in combination with RNAi mediated
knockdown of AEG-1. Inhibition of AEG-1 by shRNA signiﬁcantly
increased 5-FU sensitivity indicating that targeted downregulation
of AEG-1 might improve the expression of miR-181a-2⁄, -193b and
-193a, and inversely inhibit miR-31 and -9⁄ to mediate 5-FU kill-
ing. In our study, we demonstrate that AEG-1 confers resistance
to 5-FU by inducing the expression of miR-31 and miR-9⁄. Inhibi-
tion of AEG-1 might be exploited as a therapeutic strategy along
with 5-FU-based combinatorial chemotherapy for CRC.
In conclusion, the present study demonstrated that down-regu-
lation of AEG-1 in colorectal cancer cells results in the inhibition of
cell proliferation and colony formation in vitro. Based on these re-
sults, we conclude that AEG-1 servers as a potential molecular tar-
get for cancer treating. Also as AEG-1 directly contributes to
resistance to apoptosis and sensitivity to 5-FU, AEG-1 may serve
as an important molecular target for the discovery of new strate-
gies for cancer treatment. Targeted inhibition of AEG-1 can lead
to modiﬁcation of key elemental characteristics, such as miR-
181a-2⁄, -31, -9⁄, -193a and -193b, which may become a potential
effective therapeutic strategy for CRC.Conﬂict of interest
All authors read and approved the ﬁnal paper and they have no
competing interests.
Acknowledgments
This research was supported in part by Guangdong Natural Sci-
ence Foundation (Grant No. 10151008008000005), and Science
and Technology Planning Project of Guangdong Province (Grant
No. 2011B031800001, 2011B03180004). The authors are grateful
to all study participants and thank Guangdong General Hospital
and Sun Yat-Sen Memorial Hospital for technical support.
References
[1] Z.Z. Su et al., Identiﬁcation and cloning of human astrocyte genes displaying
elevated expression after infection with HIV-1 or exposure to HIV-1 envelope
glycoprotein by rapid subtraction hybridization, RaSH, Oncogene 21 (22)
(2002) 3592–3602.
[2] D.C. Kang et al., Cloning and characterization of HIV-1-inducible astrocyte
elevated gene-1, AEG-1, Gene 353 (1) (2005) 8–15.
[3] S.G. Lee et al., Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic
Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc, Proc. Natl. Acad.
Sci. USA 103 (46) (2006) 17390–17395.
[4] J. Li et al., Astrocyte elevated gene-1 is a novel prognostic marker for breast
cancer progression and overall patient survival, Clin. Cancer Res. 14 (11)
(2008) 3319–3326.
[5] J. Srivastava et al., Astrocyte elevated gene-1 promotes hepatocarcinogenesis:
novel insights from a mouse model, Hepatology 56 (5) (2012) 1782–1791.
[6] S. Gnosa et al., Expression of AEG-1 mRNA and protein in colorectal cancer
patients and colon cancer cell lines, J. Transl. Med. 10 (2012) 109.
S. Huang et al. / Biochemical and Biophysical Research Communications 444 (2014) 338–345 345[7] C. Yu et al., Overexpression of astrocyte elevated gene-1 (AEG-1) is associated
with esophageal squamous cell carcinoma (ESCC) progression and
pathogenesis, Carcinogenesis 30 (5) (2009) 894–901.
[8] B.K. Yoo et al., Astrocyte elevated gene-1 regulates hepatocellular carcinoma
development and progression, J. Clin. Invest. 119 (3) (2009) 465–477.
[9] H. Song et al., Prognostic signiﬁcance of AEG-1 expression in colorectal
carcinoma, Int. J. Colorectal Dis. 25 (10) (2010) 1201–1209.
[10] N. Kikuno et al., Knockdown of astrocyte-elevated gene-1 inhibits prostate
cancer progression through upregulation of FOXO3a activity, Oncogene 26
(55) (2007) 7647–7655.
[11] L. Song et al., Over-expression of AEG-1 signiﬁcantly associates with tumour
aggressiveness and poor prognosis in human non-small cell lung cancer, J.
Pathol. 219 (3) (2009) 317–326.
[12] Z. Ying, J. Li, M. Li, Astrocyte elevated gene 1: biological functions and
molecular mechanism in cancer and beyond, Cell Biosci. 1 (1) (2011) 36.
[13] B.K. Yoo et al., Identiﬁcation of genes conferring resistance to 5-ﬂuorouracil,
Proc. Natl. Acad. Sci. USA 106 (31) (2009) 12938–12943.
[14] B.K. Yoo et al., Molecular mechanism of chemoresistance by astrocyte elevated
gene-1, Cancer Res. 70 (8) (2010) 3249–3258.
[15] F. Zhang et al., Astrocyte elevated gene-1 interacts with beta-catenin and
increases migration and invasion of colorectal carcinoma, Mol. Carcinog. 52 (8)
(2013) 603–610.
[16] L. Emdad et al., Astrocyte elevated gene-1 (AEG-1) functions as an oncogene
and regulates angiogenesis, Proc. Natl. Acad. Sci. USA 106 (50) (2009) 21300–
21305.[17] S.G. Lee et al., Astrocyte elevated gene-1 activates cell survival pathways
through PI3K-Akt signaling, Oncogene 27 (8) (2008) 1114–1121.
[18] L. Emdad et al., Activation of the nuclear factor kappaB pathway by astrocyte
elevated gene-1: implications for tumor progression and metastasis, Cancer
Res. 66 (3) (2006) 1509–1516.
[19] D. Sarkar et al., Molecular basis of nuclear factor-kB activation by Astrocyte
elevated gene-1, Cancer Res. 68 (5) (2008) 1478–1484.
[20] H. Hu et al., MicroRNA-193b modulates proliferation, migration, and invasion
of non-small cell lung cancer cells, Acta Biochim. Biophys. Sin. (Shanghai) 44
(5) (2012) 424–430.
[21] C. Xu et al., MicroRNA-193b regulates proliferation, migration and invasion in
human hepatocellular carcinoma cells, Eur. J. Cancer 46 (15) (2010) 2828–
2836.
[22] J. Chen et al., MicroRNA-193b represses cell proliferation and regulates cyclin
D1 in melanoma, Am. J. Pathol. 176 (5) (2010) 2520–2529.
[23] D. Iliopoulos, A. Rotem, K. Struhl, Inhibition of miR-193a expression by Max
and RXRalpha activates K-Ras and PLAU to mediate distinct aspects of cellular
transformation, Cancer Res. 71 (15) (2011) 5144–5153.
[24] C.J. Wang et al., Suppression of microRNA-31 increases sensitivity to 5-FU at an
early stage, and affects cell migration and invasion in HCT-116 colon cancer
cells, BMC Cancer 10 (2010) 616.
[25] T. Zhang, Q. Wang, D. Zhao, et al., The oncogenetic role of micRNA-31 as a
potential biomarker in oesophageal squamous cell carcinoma, Clin. Sci. 121
(2011) 437–447.
